3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Classical hematology
1
Conditions
Multiple Myeloma
2
Thrombocytopenia
1
Myelodysplastic Syndromes
1
Motor Activity
1
Leukemia
1
Hematologic Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
Cyclophosphamide
15
Antilymphocyte Serum
11
fludarabine phosphate
10
Cyclosporine
9
Busulfan
9
Peripheral Blood Stem Cell Transplantation
8
Mycophenolic Acid
7
Filgrastim
7
Methotrexate
6
Whole-Body Irradiation
5
Melphalan
5
fludarabine
4
Radiotherapy
4
Methylprednisolone
4
Cord Blood Stem Cell Transplantation
4
Tacrolimus
3
Psychiatric Rehabilitation
3
Palliative Care
3
Blood Specimen Collection
3
sargramostim
2
Thiotepa
2
Therapeutics
2
Stem Cell Transplantation
2
Polymerase Chain Reaction
2
Injections
2
Granulocyte Colony-Stimulating Factor
2
Dexamethasone
2
Cytarabine
2
Behavior Therapy
2
Ascorbic Acid
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Myelodysplastic Syndromes
×
Platelet Transfusion
×
Clear all
NCT01615146
2015-09-02
OPTIMAL
Ottawa Hospital Research Institute
Phase NA
Terminated
9 enrolled